Global Technologies, Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- H. Wyatt Flippen
- Full Time Employees
- 2
- Sector
- Technology
- Industry
- Media & Entertainment
- Address
- 806 Green Valley Road Greensboro NC United States of America 27408
- IPO Date
- Mar 7, 1995
- CIK
- 0000932021
- Website
- globaltechnologiesltd.info
- Similar Companies
- Business
- Global Technologies, Ltd. (GTLL) operates as a multi-operational company focused on innovation in health, wellness, and technology sectors; it provides strategic consulting and procurement services specializing in go-to-market planning and execution for health and wellness companies, pharmaceutical distribution through its subsidiary Primecare Supply, LLC, AI-powered digital platforms for ordering, compliance automation, CRM management, and operational analytics, as well as business and consumer portals. The company maintains operations primarily in the United States, targeting wellness providers, pharmaceutical networks, and consumer markets in digital health. Founded in 1999 and headquartered at 806 Green Valley Road, Suite 200, Greensboro, North Carolina, GTLL employs a lean structure with key leadership including CEO and Chairman H. Wyatt Flippen and President Fredrick K. Cutcher. In recent strategic developments, GTLL launched Primecare Supply, LLC in May 2025, executing a revenue share agreement capturing 75% of gross margins above supplier floor prices for FDA-compliant pharmaceutical sales and a master licensing agreement for AI tools with 2.5% transaction fees over 24 months. The company pivoted to digital health and wellness amid FDA disruptions in GLP-1 compounding, discontinuing its clean energy segment including EV charging via GOe3, LLC, and appointing H. Wyatt Flippen as Chairman while streamlining operations for scalable growth. GTLL continues expanding consumer-facing wellness plans, therapeutic products, and reseller relationships through integrated digital infrastructure.
Yemen's Houthis Could Cause a Global Oil Shock That Rattles Markets
Santander Consolidates Global Tech Platforms to Drive Record Profits
Why Abacus Global Management, Inc. (ABX) is a Top Momentum Stock for the Long-Term
Is Abacus Global Management, Inc. (ABX) Stock Outpacing Its Finance Peers This Year?
3 Global Social Media Giants: Buy, Sell or Hold?
3 ETFs That Give Investors Access to Global Tech Beyond the U.S.
Battle of Real Estate ETFs: Vanguard Real Estate ETF Offers Lower Fees, While FlexShares Global Quality REIT Fund Delivers International Exposure
Holland America and Rolling Stone Debut New Rock Show on Oosterdam; One of Four New World Stage Productions Created with RWS Global
Treasure Global's Subsidiary Tadaa Capital Acquires Cigar Secret to Develop an AI-Power Premium Lifestyle Membership Ecosystem
Global Water Resources Sets Second Quarter 2026 Conference Call for Thursday, August 13, 2026 at 1:00 p.m. ET
Axe Compute Secures Over $1.3 Billion in Global AI Infrastructure Customer Contracts
Cognyte Appoints Adam Philpott as Chief Revenue Officer to Lead Global Market Expansion
VENU Selects Legends Global to Lead Venue Management at Regent Bank Amphitheater in Oklahoma
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Humanoid Global Highlights Formic's Role in Launching Robots for America and Announces Leadership and Membership Updates for the U.S. Robotics Coalition
VENHUB INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating VenHub Global, Inc. on Behalf of VenHub Stockholders and Encourages Investors to Contact the Firm
Ryan MacKay Promoted to Portfolio Manager on Loomis Sayles Global Fixed Income Team
Zeta Global to Announce Second Quarter 2026 Results on August 4, 2026
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?